A share price of Bio-Techne Corporation [TECH] is currently trading at $71.92, down -0.73%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TECH shares have lost -2.14% over the last week, with a monthly amount drifted -3.12%, and not seem to be holding up well over a long-time horizon.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
On 15, March 2023, BIO-TECHNE ANNOUNCES COMPLETION OF CELL AND GENE THERAPY CATAPULT PROCESS ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM. In a post published today on Yahoo Finance, Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technologies.
From an analyst’s perspective:
Bio-Techne Corporation [NASDAQ: TECH] stock has seen the most recent analyst activity on January 10, 2023, when Wells Fargo upgraded its rating to a Equal Weight but kept the price target unchanged to $90 for it. Previously, Deutsche Bank started tracking the stock with Buy rating on December 14, 2022, and set its price target to $100. On December 12, 2022, upgrade upgraded it’s rating to Buy and revised its price target to $100 on the stock. RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and suggested a price target of $89 on December 07, 2022. Credit Suisse initiated its recommendation with a Outperform and recommended $465 as its price target on August 25, 2022. Wells Fargo downgraded its rating to Underweight for this stock on April 25, 2022, but kept the price target unchanged to $370. In a note dated September 15, 2021, KeyBanc Capital Markets upgraded an Overweight rating on this stock but restated the target price of $600.
Bio-Techne Corporation experienced fluctuations in its stock price throughout the past year between $68.00 and $113.81. Bio-Techne Corporation [NASDAQ: TECH] shares were valued at $71.92 at the most recent close of the market.
Analyzing the TECH fundamentals
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 71.06 points at the first support level, and at 70.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 73.04, and for the 2nd resistance point, it is at 74.16.
Bio-Techne Corporation [TECH] reported earnings per share of $0.47 for its fiscal quarter that ended on 12/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.62/share, meaning a difference of -$0.15 and a surprise factor of -24.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2022 were $0.44 per share as compared to estimates of $0.59 per share, a difference of -$0.15 representing a surprise of -25.40%.
Ratios To Look Out For
A current ratio of 4.40 is a noteworthy aspect of Bio-Techne Corporation [NASDAQ:TECH].
Transactions by insiders
In the past 3 months, 1 insiders have purchased 407,364 shares, and 1 have sold 255,837 shares. Recent insider trading involved Furlow Brenda S., SVP – GENERAL COUNSEL, that happened on Dec 08 when 7450.0 shares were sold. SVP – GENERAL COUNSEL, Furlow Brenda S. completed a deal on Dec 07 to sell 800.0 shares. Meanwhile, Director HIGGINS JOHN L sold 512.0 shares on Aug 11.